Holen Sie sich die Stockscreener-App
14.22
5.18%
0.70
Schlusskurs vom Vortag:
$13.52
Offen:
$13.45
24-Stunden-Volumen:
676.80K
Relative Volume:
0.47
Marktkapitalisierung:
$925.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-130.41M
KGV:
-6.3482
EPS:
-2.24
Netto-Cashflow:
$-67.76M
1W Leistung:
-0.97%
1M Leistung:
+48.28%
6M Leistung:
+254.61%
1J Leistung:
+70.30%
1-Tages-Spanne:
$13.27
$14.38
1-Wochen-Bereich:
$12.94
$14.58
52-Wochen-Spanne:
$3.5001
$14.62
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Firmenname
Monte Rosa Therapeutics Inc
Sektor
Branche
Telefon
617-949-2643
Adresse
321 HARRISON AVENUE, BOSTON
Vergleichen Sie GLUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
14.22 | 880.39M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Eingeleitet | UBS | Buy |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
Alle ansehen
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Price momentum metrics for Monte Rosa Therapeutics Inc. explainedChart Signals & Proven Capital Preservation Tips - newser.com
Los Angeles Capital Management LLC Makes New Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics finds novel molecular glue degrader - Traders Union
What to do if you’re stuck in Monte Rosa Therapeutics Inc.July 2025 Snapshot & AI Forecasted Entry/Exit Points - newser.com
Integrated Quantitative Investments LLC Acquires New Holdings in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
22,500 Shares in Monte Rosa Therapeutics, Inc. $GLUE Acquired by Bailard Inc. - MarketBeat
What analysts say about Monte Rosa Therapeutics Inc stockFibonacci Retracement Levels & Free Explosive Earning Power - earlytimes.in
Is Monte Rosa Therapeutics Inc. meeting your algorithmic filter criteriaEarnings Miss & Verified Trade Idea Suggestions - newser.com
Is it time to cut losses on Monte Rosa Therapeutics Inc.Quarterly Investment Review & Entry and Exit Point Strategies - newser.com
Why Monte Rosa Therapeutics Inc. stock could benefit from AI revolutionMarket Volume Summary & Technical Pattern Alert System - newser.com
Custom watchlist performance reports with Monte Rosa Therapeutics Inc.Quarterly Growth Report & Community Driven Trade Alerts - newser.com
Why Monte Rosa Therapeutics Inc. stock is popular among millennialsJuly 2025 Highlights & Fast Moving Market Watchlists - newser.com
Published on: 2025-11-14 03:37:36 - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Applied Therapeutics (APLT) and Xilio Therapeutics (XLO) - The Globe and Mail
Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month HighHere's Why - MarketBeat
Chart based exit strategy for Monte Rosa Therapeutics Inc.July 2025 Reactions & Safe Capital Growth Tips - newser.com
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Gap DownHere's Why - MarketBeat
GLUE Stock Price and Chart — NASDAQ:GLUE - TradingView
Forecasting Monte Rosa Therapeutics Inc. price range with options dataJuly 2025 Decliners & Long-Term Growth Plans - newser.com
Monte Rosa (NASDAQ:GLUE) Nasdaq Today Shapes Biotech Path - Kalkine Media
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 10.8% Following Analyst Upgrade - MarketBeat
Monte Rosa Therapeutics, Inc. Experiences Valuation Adjustment Amid Strong Market Performance - Markets Mojo
Monte Rosa Therapeutics Hits Day High with 8.42% Surge in Stock Price - Markets Mojo
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases - The Manila Times
Published on: 2025-11-09 01:22:15 - newser.com
Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target Raised to $13.00 - MarketBeat
Monte Rosa Therapeutics Presents Promising Preclinical Data on MRT-8102 as a Novel Therapeutic for Inflammatory Cardiovascular Diseases at AHA Scientific Sessions 2025 - Quiver Quantitative
Monte Rosa Therapeutics Presents Preclinical Data at AHA - GlobeNewswire
Monte Rosa Therapeutics Hits New 52-Week High of $13.59 - Markets Mojo
Wells Fargo Maintains Monte Rosa Therapeutics (GLUE) Equal-Weight Recommendation - Nasdaq
Monte Rosa Therapeutics Advances with MRT-8102: A Promising Phase 1 Study - MSN
Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month High After Strong Earnings - MarketBeat
Monte Rosa Therapeutics Reports Strong Revenue Growth - TipRanks
Monte Rosa Therapeutics: Q3 Earnings Snapshot - CT Insider
Analysts Are Bullish on Top Healthcare Stocks: Sutro Biopharma (STRO), Black Diamond Therapeutics (BDTX) - The Globe and Mail
Novartis Deal Shines Light On Monte Rosa’s Growth Plans - Finimize
Vanguard Group Inc Reduces Stake in Monte Rosa Therapeutics Inc - GuruFocus
Finanzdaten der Monte Rosa Therapeutics Inc-Aktie (GLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):